Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paracetamol + fexofenadine + phenylephrine is a fixed-dose combination medication used primarily for the symptomatic treatment of the common cold, allergic rhinitis, and related upper respiratory tract conditions. The combination contains three active ingredients with complementary mechanisms: - Paracetamol (acetaminophen) is an analgesic and antipyretic that works by inhibiting cyclooxygenase enzymes (COX-1, COX-2, COX-3) in the central nervous system to reduce pain and fever. - Fexofenadine is a second-generation antihistamine that selectively blocks histamine H1 receptor without significant sedative or anticholinergic effects, thereby relieving symptoms such as sneezing, runny nose, watery eyes, and itching. - Phenylephrine is a sympathomimetic decongestant that acts as an agonist at alpha1-adrenergic receptor in nasal mucosal arterioles to cause vasoconstriction and reduce nasal congestion. This combination provides effective relief from multiple symptoms associated with colds and allergies—including nasal congestion, rhinorrhea (runny nose), sneezing, sore throat, fever, headache, and body aches. Clinical studies have shown it to be both safe and effective for short-term use in adults[5][6][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + fexofenadine + phenylephrine.